BAX69 is an anti-macrophage migration inhibitory factor (anti-MIF) antibody. MIF is a pro-inflammatory cytokine that is up-regulated in many human cancers and contributes to growth, angiogenesis and migration of cancer cells. BAX69 is administered intravenously every 2 weeks in a 28 day cycle in patients with malignant solid tumors.
BGJ398 is an orally bioavailable inhibitor of human fibroblast growth factor receptor (FGFRs) with potential antiangiogenic and antineoplastic activities. BYL719 is an oral selective PI3K a isoform inhibitor. In this Phase I study BGJ398 in combination with BYL719 is administered in patients with select solid tumors that have PIK3CA gene mutation with or without FGFR genetic alteration.
CBL0137 is a small molecule in the carbazole family affecting p53 and NF-kappa B signal transduction pathways. It is administered intravenously on days 1, 8 and 15 every 28 days in patients with metastatic or advanced solid tumors and refractory lymphomas.
GSK2118436 is an orally bioavailbale inhibitor of B-raf protein which may inhibit the proliferation of tumor cells with mutated BRAF gene. It is administered in patients with V600 BRAF mutation positive tumors. Previous exposure to BRAF inhibitors is allowed.
IMGN853 is an immunoconjugate consisting of the humanized monoclonal antibody against folate receptor 1 (FOLR1) conjugated to the cytotoxic maytansinoid DM4. It is administered once every 21 days intravenously in patients with advanced solid tumors with FOLR1 expression. Tumor types which have a high incidence of FOLR1 positivity (serous or endometroid epithelial ovarian cancer, serous endometrial cancer, NSCLC of adenocarcinoma and bronchoalveolar cancer and clear cell renal carcinoma) can enroll without the specific testing.
LDE225 is an oral selective Smo antagonist that downregulates the Hedgehog signal transduction pathway. In this Phase I study the patients with advanced solid tumors receive LDE225 with Warfarin or Bupropion to evaluate the drug-drug interaction.